Clinical Analysis of Bloodstream Infection of Escherichia coli in Patients with Pancreatic Cancer from 2011 to 2019

Table 5

Analysis of drug resistance of E. coli BSI in pancreatic cancer and nonpancreatic patients.

Antibiotic	Pancreatic cancer (n = 100)	Nonpancreatic cancer (n = 597)	P value
ESBL	49.0	48.1	0.898
Ampicillin	82.0	80.6	0.799
Piperacillin	60.0	61.6	0.817
Ampicillin/sulbactam	52.0	45.1	0.329
Piperacillin/tazobactam	3.0	2.7	0.766
Cefazolin	55.0	51.4	0.61
Cefuroxime	49.0	50.3	0.854
Ceftazidime	23.0	20.8	0.707
Ceftriaxone	51.0	49.7	0.854
Cefepime	16.0	12.7	0.506
Cefotetan	2.0	2.2	0.693
Aztreonam	30.0	30.2	0.975
Imipenem	0.0	0.2	0.803
Meropenem	0.0	0.2	0.803
Amikacin	3.0	0.8	0.268
Gentamicin	39.0	48.7	0.167
Tobramycin	10.0	10.7	0.871
Ciprofloxacin	39.0	50.9	0.091
Levofloxacin	38.0	48.1	0.149
Sulfamethoxazole	57.0	60.1	0.656